ticagrelor + ASA + Placebo+ASA
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cerebrovascular Accident
Conditions
Cerebrovascular Accident, Cerebrovascular Accident, Acute
Trial Timeline
Sep 1, 2017 → Oct 31, 2019
NCT ID
NCT04962451About ticagrelor + ASA + Placebo+ASA
ticagrelor + ASA + Placebo+ASA is a approved stage product being developed by AstraZeneca for Cerebrovascular Accident. The current trial status is completed. This product is registered under clinical trial identifier NCT04962451. Target conditions include Cerebrovascular Accident, Cerebrovascular Accident, Acute.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04962451 | Approved | Completed |
Competing Products
14 competing products in Cerebrovascular Accident
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM872 (zonampanel) | Astellas Pharma | Phase 2 | 52 |
| donepezil hcl | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 85 |
| ONO-2506 | Ono Pharmaceutical | Phase 2/3 | 65 |
| Abciximab | Eli Lilly | Phase 3 | 77 |
| atomoxetine + Stimulants | Eli Lilly | Pre-clinical | 23 |
| Valsartan | Novartis | Pre-clinical | 23 |
| Atorvastatin | Pfizer | Approved | 84 |
| Rivaroxaban | Bayer | Pre-clinical | 20 |
| Darolutamide (BAY1841788) + Enzalutamide | Bayer | Phase 1 | 30 |
| Botulinum toxin type A + Placebo | Ipsen | Approved | 82 |
| Atorvastatin 20mg | Brain Biotech | Approved | 77 |
| Autologous bone marrow mononuclear cell transplantation | Brain Biotech | Phase 1 | 25 |
| Roflumilast Oral Tablet | Brain Biotech | Phase 2 | 44 |